GlassScriptPhysician profile
Keith M Marshall
NPI 1770804288
$3,031.97
in general payments reported to CMS, 2019-2025
27 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.58 · 2021: $26.26 · 2022: $214 · 2023: $621 · 2024: $956 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,730 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,730.47 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $518.87 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $467.73 | 2023-2025 | |
| Lilly USA, LLC | $424.70 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $254.21 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $157.74 | 2024-2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $151.01 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $114.86 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $104.69 | 2022-2024 | Freestyle Libre 2 |
| Exact Sciences Corporation | $102.33 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $92.72 | 2024-2025 | |
| Lundbeck LLC | $78.42 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.65 | 2024-2025 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $67.46 | 2024 | Keveyis |
| Merck Sharp & Dohme LLC | $66.83 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Axsome Therapeutics, INC. | $51.91 | 2024-2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $40.10 | 2023 | Quviviq |
| Amgen INC. | $36.12 | 2022-2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $35.10 | 2022-2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $30.48 | 2022 | |
| Shield Therapeutics INC | $24.18 | 2023 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $23.66 | 2022 | |
| Corcept Therapeutics | $22.66 | 2025 | Korlym |
| Sanofi Pasteur INC. | $22.58 | 2019 | |
| Intuitive Surgical, INC. | $20.68 | 2023 | Da Vinci Surgical System |
| Ferring Pharmaceuticals INC. | $19.74 | 2023 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.69 | 2025 | Jardiance |
| Optinose US, INC. | $13.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.